



Sample Received: **May 29, 2026**COA Issued: **June 1, 2026****PRODUCT INFORMATION**

Vendor: **Upgrade** Sample Name: **PT-141 10mg** Sample Type: **Nasal spray** Lot Number: **70-202605-81** MW (g/mol): **1025.2**

ANALYTICAL METHODS**Identity:** Confirmed via MALDI-MS**Purity:** RP-HPLC (214 nm)**Content:** HPLC quantitation**TEST RESULTS**

Specification	Result	Method	Status
Identity: PT-141	PT-141	MALDI-MS	✓ Conforms
Content	11.13 mg	HPLC Quantitation	✓ Conforms
Overall Purity	99.9 %	RP-HPLC (214 nm)	✓ Conforms
Endotoxin	<0.05 EU/mL	<USP85>	✓ Conforms

HPLC Chromatogram (Retention Time: 9.862 min)**Certification:** This COA confirms that the tested material meets or exceeds Bioviridian's analytical quality specifications for peptide research use.Visit: <https://bioviridians.com/coa-search.html>*Shane Straight***Shane Straight, M.S.**
Principal Chemist, Bioviridian Inc.